The Journal of laryngology and otology · 2025
Pre-operative intratympanic gentamicin in patients undergoing retrosigmoid resection of large vestibular schwannomas: a pilot study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Potdar Tejal, Slim M Afiq M, Kontorinis Georgios
Аннотация
PURPOSE: To assess the effects of intratympanic gentamicin on the recovery of patients with large vestibular schwannomas undergoing retrosigmoid resection.
METHODS: We conducted a prospective case-control pilot study over 24 months, including 13 patients with large vestibular schwannomas (25-41 mm intracranial diameter); seven patients received intratympanic gentamicin pre-operatively, while six did not. Outcome measures were duration of stay (main), age, gender, vestibular schwannoma size, body mass index and financial costs.
RESULTS: Age had the highest association with longer inpatient stay. The non-gentamicin patients had longer hospital stays, were older, had lower body mass indices and larger vestibular schwannomas. A trend towards shorter stay was seen in patients receiving gentamicin with tumours less than 35 mm in size, but not in patients with larger tumours. Costs were lower for the gentamicin group.
CONCLUSION: Although not statistically significant, there was a positive trend in patients with vestibular schwannomas greater than 35 mm in size; thus, intratympanic gentamicin as prehabilitation could be considered.
METHODS: We conducted a prospective case-control pilot study over 24 months, including 13 patients with large vestibular schwannomas (25-41 mm intracranial diameter); seven patients received intratympanic gentamicin pre-operatively, while six did not. Outcome measures were duration of stay (main), age, gender, vestibular schwannoma size, body mass index and financial costs.
RESULTS: Age had the highest association with longer inpatient stay. The non-gentamicin patients had longer hospital stays, were older, had lower body mass indices and larger vestibular schwannomas. A trend towards shorter stay was seen in patients receiving gentamicin with tumours less than 35 mm in size, but not in patients with larger tumours. Costs were lower for the gentamicin group.
CONCLUSION: Although not statistically significant, there was a positive trend in patients with vestibular schwannomas greater than 35 mm in size; thus, intratympanic gentamicin as prehabilitation could be considered.